Oncology Update: Anamorelin
Palliative Care: Research and Treatment · 2017
DOI: 10.1177/1178224217726336 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Palliative Care: Research and Treatment, 2017. Verfasst von Eric Prommer. Beteiligte Einrichtung: UCLA/ VA Hospice & Palliative Medicine UCLA School of Medicine, Los Angeles, CA, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Cancer cachexia is a catabolic syndrome associated with uncontrolled muscle breakdown. There may be associated fat loss. Occurring in high frequency in advanced cancer, it is an indicator of poor prognosis. Besides weight loss, patients experience a cluster of symptoms including anorexia, early satiety, and weakness. The 3 stages of cachexia include stages of precachexia, cachexia, and refractory cachexia. Refractory cachexia is associated with active catabolism or the presence of factors that make active management of weight loss no longer possible. Patients with refractory cachexia often receive glucocorticoids or megasterol acetate. Glucocorticoid effect is short and responses to megasterol are variable. Anamorelin is a new agent for cancer anorexia-cachexia, with trials completed in advanced lung cancer. Acting as an oral mimetic of ghrelin, it improves appetite and muscle mass. This article reviews the pharmacology, pharmacodynamics, and effect on cancer cachexia.
Methods
A PubMed search was done using the Medical Subject Headings term anamorelin. Articles were selected to provide a pharmacologic characterization of anamorelin.
Results
Anamorelin increases muscle mass in patients with advanced cancer in 2-phase 3 trials.
Conclusions
Anamorelin improves anorexia-cachexia symptoms in patients with advanced non–small-cell lung cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UCLA/ VA Hospice & Palliative Medicine UCLA School of Medicine, Los Angeles, CA, USA.
Zitieren
APA
Prommer, E. (2017). Oncology Update: Anamorelin. Palliative Care: Research and Treatment. https://doi.org/10.1177/1178224217726336
Vancouver
Prommer E. Oncology Update: Anamorelin. Palliative Care: Research and Treatment. 2017. doi:10.1177/1178224217726336
BibTeX
@article{Prommer2017,
author = {Prommer, Eric},
title = {Oncology Update: Anamorelin},
journal = {Palliative Care: Research and Treatment},
year = {2017},
doi = {10.1177/1178224217726336}
}
EUVIMED